Jul. 15 at 2:54 PM
$AMRN 🟢 down bad, not out — catalyst list stacking
Weak hands bailing on every red candle. That’s the setup, not the problem.
🔬 LR-EtEPA ,the big one. Lymph-releasing EPA reformulation patent (US20240165066A1), NOT bioequivalent to Vascepa = generics can’t just copy it. Could extend IP moat toward 2040s. Still pending grant, watching docket closely.
📅 Q2 earnings 7/29, 8am ET call — Q1 already showed rev growth + 2nd straight positive cash flow qtr.
🇪🇺 VAZKEPA Europe ,Recordati deal, 59 countries, protection to 2039.
⚖️ Hikma/SCOTUS ,remanded 6/4, settlement path still live.
📊 2026 ACC/AHA guidelines now formally back IPE for CV risk.
$14-15 held as floor multiple times this month. Stacked catalysts + shakeout = textbook accumulation zone.
Zoom out, stay patient. 🚀
